PositiveID announced that it has completed development of its RFID glucose-sensing microchip, GlucoChip, which will accurately measure glucose levels in individuals with diabetes.
The lab tested a stable and reproducible closed cycle, continuous glucose sensing system that functions in the human blood fractions that are relevant to glucose sensing in the human body. According to the 2011 National Diabetes Fact Sheet, more than 25 million children and adults in the U.S. have diabetes, or over 8 % of the population.
GlucoChip is FDA cleared and based on PositiveID’s VeriChip microchip used for patient identification. The embedded bio-sensor system utilizes RFID technology and includes a remote transponder in wireless communication with an implantable passively-powered on-chip transponder.
The company believes the measurement of glucose levels through this system will allow individuals with diabetes to monitor glucose levels in a less invasive manner.